Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
AnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic Sclerosis
-
VEON and Kyivstar Welcome Former U.S. Secretary of State and Kyivstar Board member Mike Pompeo to Ukraine
-
Lleida.net signs with Colombian insurer Seguros Mundial for the management of its certified notifications
-
8/2024・Trifork Holding AG – Weekly report on share buyback
-
Flash News: OKX Wallet Partners with BTC Pixel War & BTCBOT to Offer Seamless User Experience
-
Flash News: OKX Wallet Partners with BTC Pixel War & BTCBOT to Offer Seamless User Experience
-
Borregaard ASA: Shares for employees 2024
-
Cornish Metals Reports Successful Exploration Drilling at Wide Formation Target, South Crofty Tin Project
-
Nokia signs 5G patent cross-license agreement with vivo
-
Introba Appoints Richard Hansen as Regional Director for the UK and Europe
-
Dexia: Dexia and Mount Street sign an agreement for the management of Dexia's bond portfolio
-
Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
-
Wouter Devriendt to step down from ABN AMRO’s Supervisory Board
-
AS Tallink Grupp Statistics for January 2024
-
NB Private Equity Partners Announces Transaction in Own Shares
-
Transaction in Own Shares
-
Nokia signs 5G patent cross-license agreement with vivo
-
-
Market update - February 5
-
Oma Savings Bank Plc’s Financial Statements Release 1 January – 31 December 2023: Record result and additional dividend to shareholders
-
BGHL (GBP): NAV(s)
-
BGHL (EUR): NAV(s)
-
BGHL (EUR): NAV(s)
-
Start of Day Message
-
TGS and SLB Announce Engagement Phase 5 in the U.S. Gulf of Mexico
-
ING to propose Deloitte as new external auditor
-
Valneva Announces Sale of Priority Review Voucher for $103 Million
-
Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma
-
Bragar Eagel & Squire, P.C. Is Investigating Spirit, Equity, and SiTime and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AlloVir, GrafTech, Instacart, and Boeing and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lovesac, Maison Solutions, Dada, and Future FinTech and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eagle Pharmaceuticals, Golden Heaven, Inspire Medical, and Driven and Encourages Investors to Contact t
-
Christina Lake Announces Results of AGM
-
ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Golden Heaven Group Holdings Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – GDHG
-
NOVONIX Appoints Sharan Burrow AC to Board of Directors
-
WVA Condemns FCTC COP10's Exclusion of Consumers and Misguided Harm Reduction Policies
-
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected L
-
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action – EGRX
-
Flash News: OKX Wallet Now Integrated with ClayStack, a Decentralized Liquid Staking Platform
-
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Evolution AB (publ) Investors to Secure Counsel Before Important Deadline in Securities Class Action – EVVTY
-
Flash News: OKX Wallet Now Integrated with RabbitX, a Permissionless Perpetuals and Derivatives Exchange
-
ROSEN, A RANKED AND LEADING FIRM, Encourages Inspire Medical Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INSP
-
China Medical System (00867） Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro®
-
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
-
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
-
Ontario workers rally against Ford’s corruption, closures and cost-of-living crisis
-
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular
-
Moutai Paints the Boundless “MEI” of 2024 with the World!
-
Religious Freedom Requires Constant Protection - Speakers Tell UPF, Washington Times Foundation Event
-
TR-1: Standard form for notification of major holdings
